Several industry groups may have outwardly shown disappointment that drug tracking standards were not included in the final FDA user fee bill, but it may have masked a collective sigh of relief.
Their defeat of the unit-level track-and-trace standards FDA wanted to implement was significant, but it also left industry uncertain of how
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?